Targeting the IL-6/JAK/STAT3 signalling axis in cancer

DE Johnson, RA O'Keefe, JR Grandis - Nature reviews Clinical …, 2018 - nature.com
Abstract The IL-6/JAK/STAT3 pathway is aberrantly hyperactivated in many types of cancer,
and such hyperactivation is generally associated with a poor clinical prognosis. In the …

Cell adhesion by integrins

M Bachmann, S Kukkurainen… - Physiological …, 2019 - journals.physiology.org
Integrins are heterodimeric cell surface receptors ensuring the mechanical connection
between cells and the extracellular matrix. In addition to the anchorage of cells to the …

[HTML][HTML] Protein kinases: drug targets for immunological disorders

L Castelo-Soccio, H Kim, M Gadina… - Nature Reviews …, 2023 - nature.com
Protein kinases play a major role in cellular activation processes, including signal
transduction by diverse immunoreceptors. Given their roles in cell growth and death and in …

World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management

W Shomali, J Gotlib - American Journal of Hematology, 2019 - Wiley Online Library
Disease overview The eosinophilias encompass a broad range of non‐hematologic
(secondary or reactive) and hematologic (primary or clonal) disorders with potential for end …

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

JW Vardiman, J Thiele, DA Arber… - Blood, The Journal …, 2009 - ashpublications.org
Recently the World Health Organization (WHO), in collaboration with the European
Association for Haematopathology and the Society for Hematopathology, published a …

Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML

JE Maxson, J Gotlib, DA Pollyea… - … England Journal of …, 2013 - Mass Medical Soc
Background The molecular causes of many hematologic cancers remain unclear. Among
these cancers are chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL1–negative) …

World Health Organization‐defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management

J Gotlib - American journal of hematology, 2017 - Wiley Online Library
Disease overview The eosinophilias encompass a broad range of nonhematologic
(secondary or reactive) and hematologic (primary, clonal) disorders with potential for end …

[HTML][HTML] MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia

Y Pikman, BH Lee, T Mercher, E McDowell… - PLoS …, 2006 - journals.plos.org
Background The JAK2V617F allele has recently been identified in patients with
polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid …

JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis

LM Scott, W Tong, RL Levine, MA Scott… - … England Journal of …, 2007 - Mass Medical Soc
Background The V617F mutation, which causes the substitution of phenylalanine for valine
at position 617 of the Janus kinase (JAK) 2 gene (JAK2), is often present in patients with …

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

A Tefferi, JW Vardiman - leukemia, 2008 - nature.com
Abstract The 2001 World Health Organization (WHO) treatise on the classification of
hematopoietic tumors lists chronic myeloproliferative diseases (CMPDs) as a subdivision of …